**Core Concept**
Chimeric human/murine monoclonal antibodies are a class of biopharmaceuticals that combine the murine (mouse) variable regions of an antibody with human constant regions. This design aims to reduce immunogenicity while retaining the antigen-binding properties of the original murine antibody.

**Why the Correct Answer is Right**
The chimeric design exploits the fact that the variable regions of an antibody are responsible for antigen recognition, whereas the constant regions are responsible for effector functions such as complement activation and antibody-dependent cellular cytotoxicity. By replacing the murine constant regions with human ones, the risk of an immune response against the antibody is significantly reduced, making it safer for human use. This approach is often used in the development of therapeutic antibodies for cancer and autoimmune diseases.

**Why Each Wrong Option is Incorrect**
**Option A:** Not applicable, as the question does not provide enough context for this option.
**Option B:** This option is incorrect because it does not accurately describe the characteristics of chimeric human/murine monoclonal antibodies.
**Option C:** This option is incorrect because it does not accurately describe the design of chimeric human/murine monoclonal antibodies.

**Clinical Pearl / High-Yield Fact**
One key advantage of chimeric human/murine monoclonal antibodies is their reduced immunogenicity, which allows for repeated dosing and improved therapeutic outcomes. This is particularly important for chronic diseases where long-term treatment is required.

**Correct Answer: D. Chimeric antibodies are a type of therapeutic antibody that combines murine and human components to reduce immunogenicity.**